Amylyx Pharmaceuticals, Inc. (AMLX)
- Previous Close
1.7700 - Open
1.7500 - Bid 1.7100 x 200
- Ask 1.7200 x 800
- Day's Range
1.6795 - 1.7500 - 52 Week Range
1.6500 - 25.8100 - Volume
773,076 - Avg. Volume
2,405,247 - Market Cap (intraday)
116.684M - Beta (5Y Monthly) -0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0700 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.08
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
amylyx.comRecent News: AMLX
Performance Overview: AMLX
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMLX
Valuation Measures
Market Cap
120.37M
Enterprise Value
-249.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
0.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.86%
Return on Assets (ttm)
-12.31%
Return on Equity (ttm)
-21.00%
Revenue (ttm)
398M
Net Income Avi to Common (ttm)
-71.09M
Diluted EPS (ttm)
-1.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
373.29M
Total Debt/Equity (mrq)
1.14%
Levered Free Cash Flow (ttm)
34.87M
Research Analysis: AMLX
Company Insights: AMLX
AMLX does not have Company Insights
Research Reports: AMLX
Daily – Vickers Top Buyers & Sellers for 04/03/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/24/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.